Type: Subsidiary
On the web: http://www.imclone.com

ImClone Systems wants to create identically successful cancer drug candidates. The company, a subsidiary of Eli Lilly, is focused on the development of oncology-related antibody therapies. The biotech research firm's only commercial product, Erbitux, is approved for treatment of colorectal cancer, as well as head and neck cancers. ImClone Systems co-promotes the drug with Bristol-Myers Squibb (BMS) in North America and with Merck KGaA elsewhere. The company is continuing to develop Erbitux as a possible treatment for other kinds of cancer, including lung cancer. It also has other potential oncology treatments in development.

Officers:
President: Bernhard Ehmer
VP and CFO: Brian Batchelder
SVP Global and Development Operations: Andreas Harstrick

Competitors:
Amgen
Genentech
OSI Pharmaceuticals

© 2012 Hoover's, Inc. All rights reserved.